Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment (Navigator)

5. august 2026 oppdatert av: Expedition Therapeutics, Inc

A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants With COPD

This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

600

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

  • Forente stater
    • Arizona
      • Phoenix, Arizona, Forente stater, 85012
        • Rekruttering
        • DM Clinical Research - Phoenix
        • Hovedetterforsker:
          • Danielle Armas
        • Ta kontakt med:
    • California
      • Northridge, California, Forente stater, 91324
        • Rekruttering
        • California Medical Research Associates Inc.
        • Hovedetterforsker:
          • Jigar Kadakia
        • Ta kontakt med:
    • Colorado
      • Aurora, Colorado, Forente stater, 80012
        • Rekruttering
        • Lynn Institute of Denver
        • Hovedetterforsker:
          • Timothy Colander
        • Ta kontakt med:
    • Florida
      • Altamonte Springs, Florida, Forente stater, 32701
        • Rekruttering
        • International Clinical Research
        • Ta kontakt med:
        • Hovedetterforsker:
          • Feldman
      • Crystal River, Florida, Forente stater, 34229
        • Rekruttering
        • Nature Coast Clinical Research
        • Ta kontakt med:
        • Hovedetterforsker:
          • Potu
      • Leesburg, Florida, Forente stater, 34748
        • Rekruttering
        • Clinical Site Partners, LLC Leesburg dba Flourish Research
        • Ta kontakt med:
      • Miami, Florida, Forente stater, 33135
        • Rekruttering
        • Suncoast Research Group, LLC Miami - Little Havana dba Flourish Research
        • Hovedetterforsker:
          • Mark Kutner
        • Ta kontakt med:
      • Orange, Florida, Forente stater, 32763
        • Rekruttering
        • Optimal Research Sites
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kristyna Paradis
    • Georgia
      • Rincon, Georgia, Forente stater, 31326
        • Har ikke rekruttert ennå
        • Centricity Research Columbus
        • Hovedetterforsker:
          • Maria Mascolo
        • Ta kontakt med:
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46254
        • Rekruttering
        • DM Clinical Research-Indianapolis
        • Hovedetterforsker:
          • Brandon Essink
        • Ta kontakt med:
    • Kansas
      • Topeka, Kansas, Forente stater, 66606
        • Rekruttering
        • Cotton O'Neil Clinical Research Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Najm Salah
    • Minnesota
      • Maplewood, Minnesota, Forente stater, 55109
    • North Carolina
      • Shelby, North Carolina, Forente stater, 28150
        • Rekruttering
        • Carolina Research Center, Inc.
        • Hovedetterforsker:
          • Jones
        • Ta kontakt med:
    • Ohio
      • Columbus, Ohio, Forente stater, 43215
        • Rekruttering
        • Remington-Davis Research
        • Ta kontakt med:
        • Hovedetterforsker:
          • Cordasco
    • Pennsylvania
      • DuBois, Pennsylvania, Forente stater, 15801
        • Rekruttering
        • Clinical Research Associates of Central PA, LLC
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bansal
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Rekruttering
        • DM Clinical Research - Philadelphia
        • Ta kontakt med:
        • Hovedetterforsker:
          • David Wheeler
    • Texas
      • Cypress, Texas, Forente stater, 77429
        • Rekruttering
        • Horizon Clinical Research Group.
        • Hovedetterforsker:
          • Dileep Puppala
        • Ta kontakt med:
      • Tomball, Texas, Forente stater, 77375
        • Rekruttering
        • DM Clinical Research- Tomball
        • Hovedetterforsker:
          • Mustafa Naeem
        • Ta kontakt med:
    • Virginia
      • Burke, Virginia, Forente stater, 22015
        • Rekruttering
        • Burke Internal Medicine, Inc.
        • Hovedetterforsker:
          • Nashwa Gabra
        • Ta kontakt med:
      • Virginia Beach, Virginia, Forente stater, 23456

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  1. Provided written informed consent for the study
  2. Body mass index (BMI) ≥ 18.5 kg/m2 and < 35 kg/m2 at screening (weight ≥ 50 kg for males and ≥ 45 kg for females)
  3. Diagnosis of COPD for at least 1 year
  4. COPD with physician-confirmed diagnosis of chronic bronchitis (persistent, productive cough and sputum for at least 3 months in the past year)
  5. At least 2 moderate or > 1 severe exacerbation within 12 months prior to screening
  6. Current or ex-tobacco smokers with history of ≥ 10 pack-years (1 pack year = 20 cigarettes smoked per day for 1 year);

  7. Stable maintenance therapy with either dual or triple inhaled therapy for ≥ 3 months prior to enrollment per below:

    1. Dual therapy: long-acting beta-2 agonist/muscarinic antagonist (LABA/LAMA) or inhaled corticosteroids (ICS)/LAMA, or ICS/LABA OR
    2. Triple therapy: ICS/LAMA/LABA
  8. Post-BD FEV1/FVC < 0.7 and post-BD FEV1(% predicted) ≥ 40% at Screening
  9. COPD Assessment Test (CAT) score ≥ 10 at Screening
  10. If participant is of childbearing potential, must commit to practicing highly effective methods of birth control and not donating eggs during the study and at least 14 days after the last dose.

  11. Male participants commit to the following during the study and for at least 14 days after the last dose:

    1. Practice true sexual abstinence (refrain from heterosexual intercourse)
    2. Use a condom with any female partner of childbearing potential and ensure that the partner uses a highly effective contraceptive method (eg, IUD/IUS, combined hormonal contraception, progestogen-only contraception, or bilateral tubal occlusion).
    3. Be vasectomized (≥ 3 months prior to screening)
    4. Refrain from donating sperm during the Treatment Period and for at least 14 days after the last dose of the IP

Exclusion Criteria:

  1. COPD exacerbation within the 4 weeks prior to randomization.
  2. Clinically important pulmonary disease other than COPD (eg, asthma, active lung infection, clinically significant bronchiectasis, pulmonary fibrosis, cystic fibrosis, lung cancer, alpha-1 antitrypsin deficiency, tuberculosis).
  3. Significant immunodeficiency and/or positive serological tests for hepatitis B, hepatitis C, or known human immunodeficiency virus (HIV) infection.
  4. Pneumonia requiring antibiotics or antiviral medication within 28 days prior to Visit 1.
  5. History of clinically significant infection (excluding pneumonia), acute upper or lower respiratory infection, requiring antibiotics or antiviral medication within 14 days prior to Visit 1.
  6. Evidence of active liver disease (with or without ongoing treatment)
  7. Participants with a QT interval, from the ECG conducted at Screening Visit 1, corrected with Fridericia's formula (QTcF) > 450 msec (or QTcF > 480 msec in participants with bundle branch block).
  8. Current or history, within the past year of Visit 1, of substance and/or alcohol abuse.

  9. History of cancer except:

    1. Participants who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to Visit 1
    2. Participants who have had other malignancies are eligible provided that curative therapy was completed at least 5 years prior to Visit 1
  10. Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during Screening Period, which in the opinion of the investigator, may put the participant at risk because of his/her participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
  11. Known history of allergy or reaction to any component of the investigational product formulation
  12. Current treatment with biologic drugs for COPD (eg, dupilumab, mepolizumab) or use of Therapeutics, biologics within 5 half-lives or 4 months, whichever is longer, from randomization
  13. Current long-term treatment with oxygen therapy > 12 hours per day
  14. Use of immunoglobulin or blood products in 30 days prior to Screening
  15. Received a live attenuated vaccine within 30 days prior to Screening
  16. Participants who are participating in the acute phase of a pulmonary rehabilitation program, i.e. who started rehabilitation < 4 weeks prior to screening (Note: participants in the maintenance phase of a rehabilitation program can be included).
  17. History or active conditions associated with the onset of non-hereditary palmoplantar keratosis:
  18. Have any tooth that can potentially cause pain or infection as noted in the oral exam unless they are corrected before the study

  19. Has active periodontal disease and are either:

    1. Currently treated by a dentist for this condition or
    2. Expected to have periodontal disease-related procedures within the study period
  20. Are scheduled to have tooth extraction that will occur during the study period

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: EXPD-101/FXS7553 Dose 1
Participants will receive EXPD-101/FXS7553 Dose 1, orally, once daily, for 52 weeks.
Legemiddel: EXPD-101/FXS7553 Dose 1
Oral tablet
Eksperimentell: EXPD-101/FXS7553 Dose 2
Participants will receive EXPD-101/FXS7553 Dose 2, orally, once daily, for 52 weeks.
Legemiddel: EXPD-101/FXS7553 Dose 2
Oral tablet
Placebo komparator: Placebo
Participants will receive a EXPD-101/FXS7553-matching placebo, tablets orally, once daily, for 52 weeks.
Legemiddel: Placebo
EXPD-101/FXS7553 - matching oral tablet.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Annualized rate of moderate and severe COPD exacerbations
Tidsramme: Over 52 Weeks

Effect of EXPD-101/FXS7553 compared with placebo on rate of moderate and severe COPD exacerbations.

Moderate COPD exacerbation is defined as acute exacerbations of COPD that require either systemic corticosteroids (intramuscular (IM), intravenous, or oral) and/or antibiotics.

Severe COPD exacerbation is defined as acute exacerbation of COPD requiring hospitalization or emergency room / urgent care visit ≥ 24 hours.
Over 52 Weeks
The number of participants experiencing an adverse events (AEs)
Tidsramme: Over 52 weeks
The number of participants experiencing an AE (an AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship) will be presented.
Over 52 weeks
Changes in vital sign parameters
Tidsramme: Over 52 weeks
Vital signs, including systolic and diastolic BP (mmHg), heart rate (beats per minute), body temperature (°C), and respiratory rate will be listed and summarized.
Over 52 weeks
Changes in electrocardiogram (ECG) parameters
Tidsramme: Over 52 weeks
ECG (graphical tracing that records the electrical signals of your heartbeat) parameters will be summarized.
Over 52 weeks
Number of Participants with Clinically Significant Changes in Physical Examination Findings
Tidsramme: Over 52 weeks
Physical examination will be performed at each study visit by a qualified investigator. The following body systems will be assessed: ears, nose, throat, skin, cardiovascular, respiratory, musculoskeletal, and neurological.
Over 52 weeks
Number of participants with clinically significant abnormalities
Tidsramme: Over 52 weeks
Clinical laboratory assessments including hematology, serum chemistry, and urinalysis will be performed at each study visit.
Over 52 weeks
Changes in Physical Exam Parameters - Body Weight
Tidsramme: Over 52 weeks
Body weight measured using a calibrated scale at each study visit
Over 52 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time to first moderate or severe COPD exacerbation
Tidsramme: Over 52 Weeks
Effect of EXPD-101/FXS7553 compared with placebo on time to first moderate or severe COPD exacerbation.
Over 52 Weeks
Change From Baseline in Quality of Life Questionnaire - St. George's Respiratory Questionnaire (SGRQ)
Tidsramme: Baseline, Week 52

The SGRQ is a validated, self-administered patient-reported outcome (PRO) that assesses symptoms, functioning, and health-related quality of life for participants with Chronic Obstructive Pulmonary Disease (COPD).

It contains 50 items in 2 parts. Part 1 has 8 items for assessing the severity of respiratory symptoms (cough, sputum production, wheeze, breathlessness, and the duration and frequency of attacks of breathlessness or wheeze). Part 2 has 42 items across 2 components (Activity and Impacts) related to daily activities and psychosocial impacts of the participant's respiratory condition. The SGRQ total score is calculated as the sum of scores across symptoms, activity, and effects, with 0 indicating the best possible health status and 100 indicating the worst possible health status. A decrease in 4 units in the total score corresponds to a clinically significant improvement in the quality of life.
Baseline, Week 52
Change From Baseline at Week 52 in Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1) and forced vital capacity (FVC)
Tidsramme: Baseline, Week 52

FEV1 is used to assess lung function and is the maximum amount of air that can be forced out in one second after first second after taking a forced expiration as measured by a spirometer. Postbronchodilator FEV1 tests included spirometry tests performed after administration of bronchodilator.

FVC is used to assess lung function and is the total volume of air that can be forced out after taking a deep breath as measured by a spirometer.
Baseline, Week 52
Change From Baseline at Week 52 in Quality of Life Questionnaire - Evaluating Respiratory Symptoms (E-RS): COPD
Tidsramme: Baseline, Week 52

The E-RS:COPD™ scale, a part of the EXACT tool, is a derivative instrument used to measure the effect of treatment on the severity of respiratory symptoms in stable COPD. The E-RS is an 11-item participant-reported diary to measure respiratory symptom items contained in the 14-item EXACT.

Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity. In addition to the total score, symptom domain scores can be calculated for breathlessness (5 items; score range: 0-17), cough and sputum (3 items; score range: 0-11) and chest symptoms (3 items; score range: 0-12) by summing the responses of items within a respective domain. As with the total score, higher domain scores indicate greater severity.
Baseline, Week 52
Annualized rate of severe COPD exacerbations
Tidsramme: Over 52 Weeks
Effect of EXPD-101/FXS7553 compared with placebo on rate of severe COPD exacerbations.
Over 52 Weeks
Plasma Concentration and metabolites of EXPD-101/FXS755
Tidsramme: Pre-dose at baseline, and Weeks 2, 4, 12, 28, 52 and 56.
Pre-dose at baseline, and Weeks 2, 4, 12, 28, 52 and 56.
Change from Baseline in sputum neutrophil elastase (NE) activity
Tidsramme: Over 52 Weeks
Effect of EXPD-101/FXS7553 compared with placebo on sputum neutrophil elastase (NE) activity.
Over 52 Weeks
Annualized rate of COPD exacerbations requiring Emergency Department visit and/or hospitalization
Tidsramme: Over 52 Weeks
Effect of EXPD-101/FXS7553 compared with placebo on rate of COPD exacerbations requiring Emergency Department visit and/or hospitalization.
Over 52 Weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Expedition Therapeutics, Inc

Etterforskere

  • Studiestol: James Duncan Chalmers, MBChB, PhD, Radcliffe Department of Medicine, University of Oxford

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

30. juni 2026

Primær fullføring (Antatt)

30. juni 2028

Studiet fullført (Antatt)

11. juli 2028

Datoer for studieregistrering

Først innsendt

6. mai 2026

Først innsendt som oppfylte QC-kriteriene

29. juni 2026

Først lagt ut (Faktiske)

6. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

7. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • EXPD-101-201
  • 2026-525216-34 (EudraCT-nummer)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be shared externally. Data collected in this study will be used solely for internal analysis and regulatory submission purposes, consistent with participant confidentiality protections and sponsor data governance policies.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere